AU2019350581B2 - Methods of treatment of cancer comprising Cdc7 inhibitors - Google Patents

Methods of treatment of cancer comprising Cdc7 inhibitors Download PDF

Info

Publication number
AU2019350581B2
AU2019350581B2 AU2019350581A AU2019350581A AU2019350581B2 AU 2019350581 B2 AU2019350581 B2 AU 2019350581B2 AU 2019350581 A AU2019350581 A AU 2019350581A AU 2019350581 A AU2019350581 A AU 2019350581A AU 2019350581 B2 AU2019350581 B2 AU 2019350581B2
Authority
AU
Australia
Prior art keywords
cancer
sra141
day
tumor
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019350581A
Other languages
English (en)
Other versions
AU2019350581A1 (en
Inventor
Ryan James HANSEN
Christian Andrew HASSIG
Snezana Milutinovic
Bryan William STROUSE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Carna Biosciences Inc
Original Assignee
Carna Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2019/019676 external-priority patent/WO2019165473A1/en
Application filed by Carna Biosciences Inc filed Critical Carna Biosciences Inc
Publication of AU2019350581A1 publication Critical patent/AU2019350581A1/en
Assigned to Sierra Oncology, LLC. reassignment Sierra Oncology, LLC. Amend patent request/document other than specification (104) Assignors: SIERRA ONCOLOGY, INC.
Assigned to CARNA BIOSCIENCES, INC. reassignment CARNA BIOSCIENCES, INC. Request for Assignment Assignors: Sierra Oncology, LLC.
Application granted granted Critical
Publication of AU2019350581B2 publication Critical patent/AU2019350581B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019350581A 2018-09-24 2019-08-28 Methods of treatment of cancer comprising Cdc7 inhibitors Active AU2019350581B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862735778P 2018-09-24 2018-09-24
US62/735,778 2018-09-24
US201862760638P 2018-11-13 2018-11-13
US62/760,638 2018-11-13
AUPCT/US2019/019676 2019-02-26
PCT/US2019/019676 WO2019165473A1 (en) 2018-02-26 2019-02-26 Methods of treatment of cancer comprising cdc7 inhibitors
PCT/US2019/048657 WO2020068347A1 (en) 2018-09-24 2019-08-28 Methods of treatment of cancer comprising cdc7 inhibitors

Publications (2)

Publication Number Publication Date
AU2019350581A1 AU2019350581A1 (en) 2021-04-15
AU2019350581B2 true AU2019350581B2 (en) 2025-07-10

Family

ID=69952463

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019350581A Active AU2019350581B2 (en) 2018-09-24 2019-08-28 Methods of treatment of cancer comprising Cdc7 inhibitors

Country Status (8)

Country Link
US (1) US12533353B2 (https=)
EP (1) EP3856352A4 (https=)
JP (1) JP7579781B2 (https=)
KR (1) KR20210064252A (https=)
CN (2) CN121081469A (https=)
AU (1) AU2019350581B2 (https=)
CA (1) CA3113621A1 (https=)
WO (1) WO2020068347A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019350581B2 (en) 2018-09-24 2025-07-10 Carna Biosciences, Inc. Methods of treatment of cancer comprising Cdc7 inhibitors
MX2022000729A (es) * 2019-07-19 2022-02-10 Takeda Pharmaceuticals Co Terapia de combinacion para el tratamiento del cancer.
EP4003994A4 (en) * 2019-07-31 2023-09-13 Oncour Pharma, Inc. TREATMENT OF EVASIVE IMMUNE TUMORS
WO2022013328A1 (en) * 2020-07-15 2022-01-20 Université Libre de Bruxelles Method for determining sensitivity to an antineoplastic agent
AU2024351866A1 (en) * 2023-09-27 2026-04-09 Carna Biosciences, Inc. Novel combination therapy for blood cancer
CN117563005A (zh) * 2023-10-26 2024-02-20 浙江大学 一种治疗结直肠癌的药物组合物及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8552048B2 (en) * 2006-12-26 2013-10-08 Threshold Pharmaceuticals, Inc. Phosphoramidate alkylator prodrugs for the treatment of cancer
US8742113B2 (en) * 2011-03-31 2014-06-03 Sbi Biotech Co., Ltd. Furanone derivative
US20170065609A1 (en) * 2014-01-31 2017-03-09 Carna Biosciences, Inc. Anticancer agent composition
WO2019165473A1 (en) * 2018-02-26 2019-08-29 Sierra Oncology, Inc Methods of treatment of cancer comprising cdc7 inhibitors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
JP2007501827A (ja) 2003-08-08 2007-02-01 ファルマシア・イタリア・エス・ピー・エー キナーゼ阻害剤として活性なピリミジルピロール誘導体
US20050043346A1 (en) 2003-08-08 2005-02-24 Pharmacia Italia S.P.A. Pyridylpyrrole derivatives active as kinase inhibitors
US7371862B2 (en) 2005-11-11 2008-05-13 Pfizer Italia S.R.L. Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US7618982B2 (en) 2005-12-19 2009-11-17 Nerviano Medical Sciences S.R.L. Heteroarylpyrrolopyridinones active as kinase inhibitors
BRPI0709680B8 (pt) 2006-03-27 2021-05-25 Nerviano Medical Sciences Srl derivados de pirrol, tiofeno e furano substituídos por piridil e piridimil como inibidores de quinase
AU2007240496A1 (en) 2006-04-19 2007-11-01 Novartis Ag Indazole compounds and methods for inhibition of CDC7
FR2907120B1 (fr) 2006-10-12 2013-01-11 Sanofi Aventis Nouveaux derives imidazolones,leur preparation a titre de medicaments,compositions pharmaceutiques,utilisation comme inhibiteurs de proteines kinases notamment cdc7
EP2118102B1 (en) 2006-11-28 2013-06-12 Nerviano Medical Sciences S.r.l. Tricyclic indoles and (4,5-dihydro) indoles
ES2546816T3 (es) 2007-02-27 2015-09-28 Nerviano Medical Sciences S.R.L. Isoquinolinpirrolopiridinonas activas como inhibidores de cinasa
AR069869A1 (es) 2007-12-21 2010-02-24 Exelixis Inc Derivados de benzofuro[3,2-d]pirimidinas inhibidores de proteinquinasas,composiciones farmaceuticas que los comprenden y usos de los mismos en el tratamiento del cancer.
WO2010101302A1 (en) 2009-03-05 2010-09-10 Takeda Pharmaceutical Company Limited Thienopyrimidine as cdc7 kinase inhibitors
WO2010122979A1 (ja) 2009-04-20 2010-10-28 Ｓｂｉバイオテック株式会社 チアゾリジノン誘導体
CN102471339A (zh) 2009-07-15 2012-05-23 雅培制药有限公司 激酶的吡咯并吡啶抑制剂
ES2483594T3 (es) 2009-07-15 2014-08-06 Abbott Laboratories Pirrolopirazinas inhibidoras de quinasas
AU2010319322A1 (en) 2009-11-13 2012-05-31 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
TW201127384A (en) 2009-11-18 2011-08-16 Nerviano Medical Sciences Srl Therapeutic combination comprising a Cdc7 inhibitor and an antineoplastic agent
SG183304A1 (en) 2010-02-17 2012-09-27 Takeda Pharmaceutical Heterocyclic compound
AU2011224457B2 (en) 2010-03-08 2014-11-06 Sloan-Kettering Institute For Cancer Research Cdc7 kinase inhibitors and uses thereof
US8450320B2 (en) 2010-04-16 2013-05-28 Abbvie Inc. Pyrrolopyrazinone inhibitors of kinases
EP2558459B1 (en) 2010-04-16 2014-01-22 Abbvie Inc. Phthalazin-(2h)-one inhibitors of kinases
CA2795422A1 (en) 2010-04-19 2011-10-27 Abbvie Inc. Pyrrolopyridine inhibitors of kinases
US20120135989A1 (en) 2010-06-29 2012-05-31 Crystalgenomics, Inc. Azaindole derivative
CA3042849A1 (en) 2016-11-04 2018-05-11 Carna Biosciences, Inc. Furanone derivates and methods of use thereof
AU2019350581B2 (en) 2018-09-24 2025-07-10 Carna Biosciences, Inc. Methods of treatment of cancer comprising Cdc7 inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8552048B2 (en) * 2006-12-26 2013-10-08 Threshold Pharmaceuticals, Inc. Phosphoramidate alkylator prodrugs for the treatment of cancer
US8742113B2 (en) * 2011-03-31 2014-06-03 Sbi Biotech Co., Ltd. Furanone derivative
US20170065609A1 (en) * 2014-01-31 2017-03-09 Carna Biosciences, Inc. Anticancer agent composition
WO2019165473A1 (en) * 2018-02-26 2019-08-29 Sierra Oncology, Inc Methods of treatment of cancer comprising cdc7 inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Nowak et al., "The role of chromosomal instability in tumor initiation", 2002, PNAS, 99, pgs. 16226-16231 (Year: 2002) *
Takeda, "An Open-Label, Phase 2, Parallel Arm Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 Single Agent in Patients With Metastatic Pancreatic Cancer", 2018, Takeda, pgs. 1-99 (Year: 2018) *
Zhang et al., "Multiple roles of APC and its therapeutic implications in colorectal cancer", 2017, Journal of the National Cancer Institute, 109, pgs. 1-10 (Year: 2017) *

Also Published As

Publication number Publication date
US12533353B2 (en) 2026-01-27
WO2020068347A1 (en) 2020-04-02
CN121081469A (zh) 2025-12-09
CA3113621A1 (en) 2020-04-02
KR20210064252A (ko) 2021-06-02
US20210393620A1 (en) 2021-12-23
JP2022500479A (ja) 2022-01-04
EP3856352A4 (en) 2022-06-29
JP7579781B2 (ja) 2024-11-08
CN113348020A (zh) 2021-09-03
EP3856352A1 (en) 2021-08-04
AU2019350581A1 (en) 2021-04-15

Similar Documents

Publication Publication Date Title
AU2019350581B2 (en) Methods of treatment of cancer comprising Cdc7 inhibitors
WO2019165473A1 (en) Methods of treatment of cancer comprising cdc7 inhibitors
US20250302817A1 (en) Methods for treating pten-mutant tumors
US20140348819A1 (en) Methods of Treating Cancer
JP2024012649A (ja) Ｃｈｋ１阻害剤を含む癌の治療方法
JP2014515390A (ja) Ｐｉ３ｋ阻害剤化合物を用いた中皮腫の治療法
HK1248539A1 (zh) 借助塞里班土单抗的组合治疗
JP7712955B2 (ja) 癌の治療のための投薬レジメン
US20220184091A1 (en) Methods of Treating Cancer with Chk1 Inhibitors
US20220241294A1 (en) Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating notch-activated breast cancer
CN114072526A (zh) 使用chk1抑制剂治疗癌症的方法
WO2021228146A1 (zh) 一种lsd1抑制剂的用途
AU2024356380A1 (en) Cancer treatments using mta-cooperative prmt5 inhibitors
JP2026074036A (ja) 小児患者のがんの治療方法
EA048255B1 (ru) Режим дозирования для лечения рака
BARLESI et al. AMENDMENT 7 (URGENT SAFETY MEASURE)

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: SIERRA ONCOLOGY, LLC.

Free format text: FORMER NAME(S): SIERRA ONCOLOGY, INC.

PC1 Assignment before grant (sect. 113)

Owner name: CARNA BIOSCIENCES, INC.

Free format text: FORMER APPLICANT(S): SIERRA ONCOLOGY, LLC.

FGA Letters patent sealed or granted (standard patent)